Activity value 76italy Buyer&Supplier,Last transaction date:
2026-03-31
Overview
Export data
Partners
HS Codes
Products
Areas
Ports
Trade trend analysis
Mon
|
Year
Number of TransactionsQuantityWeight
Number of TransactionsQuantityWeight
The above chart presents the market trend analysis for chiesi farmaceuticic s.p.a. from 2025 to 2026.
By examining various dimensions such as transaction quantity, transaction weight, average price,
and transaction frequency, we can gain an intuitive understanding of the company's performance in terms of procurement cycles, business scale, and stability.
As of 2026, the company has completed 119 transactions, with a transaction quantity of 1674232.46 and a transaction weight of 8365.2.
Product description
(ACTIVE PHARMACEUTICALS INGREDIENTS API) PIROXICAM BETA-CYCLODEXTRIN CAS NO. 96684-40-1 Note: for CD 5th Schedule Part II of Table-A at Sr. No. 230 for ACD: 1151(I)/2025 Sr. No. 3(iii) Date: 30-06-2025 for RD: 1152/(I)/2025 Sr. No. 2(c) Date: 30-06-2025
Expand
Product description
(ACTIVE PHARMACEUTICALS INGREDIENTS API) PIROXICAM BETA-CYCLODEXTRIN CAS NO. 96684-40-1 Note: for CD 5th Schedule Part II of Table-A at Sr. No. 230 for ACD: 1151(I)/2025 Sr. No. 3(iii) Date: 30-06-2025 for RD: 1152/(I)/2025 Sr. No. 2(c) Date: 30-06-2025
Expand
Product description
CLENIL AEROSOL NEBULISING SUSPENSION (BECLOMETHASONE MONODOSE VIALS) QTY DECLARED IN NR. DUE TO UNIT VALUE IN NR. NET WEIGHT 54.240 KGS
Expand
Product description
CLENIL AEROSOL NEBULISING SUSPENSION (BECLOMETHASONE MONODOSE VIALS) QTY DECLARED IN NR. DUE TO UNIT VALUE IN NR. NET WEIGHT 1814.40 KGS
Expand
Product description
CUROSURF STERILE SUSPENSION IN VIALS FOR INTRATRACHEAL INSTILLATION GENETIC NAME IS PORACTANT ALFA QTY DECLARED IN NR. DUE TO UNIT VALUE IN NR. NET WEIGHT 72 KGS
Expand
Product description
LAB TEST MATERIAL ( GLYCOPYRRONIUM BROMIDE CHF 5259.02 ..WORKING STANDARD ..BATCH NO 1036IM24IMPI272...MFG DATE 09.2024...EXPIRY DATE 09.2029...QUANTITY 10 VIALS OF 500 MG .....2- BECLOMETHASONE DIPROPIONATE CHF718WORKING STD ...BATCH NO 2106D02.0582400...MFG DATE 10.2024...10.2029...QUANTITY 20 VILAS OF 500MG .. 3- FORMOTEROL FUMARATE DIHYDRATE CHF1531.02.. REFERANCE STANDARD...BATCH NO 1205375...MFG DATE 09.2024...EXPIRY DATE 09.2028...QUANTITY 6 VIALS 500MG ..4- SALBUTAMOL SULFATE CHF 962.0
Expand
Product description
ATEM NEBULISER SOLUTION (IPRATROPIUM BROMIDE VIALS) MEDICINE QTY DECLARED IN NR. DUE TO UNIT VALUE IN NR. NET WEIGHT 512.500 KGS
Expand
Product description
ATEM NEBULISER SOLUTION (IPRATROPIUM BROMIDE VIALS) MEDICINE QTY DECLARED IN NR. DUE TO UNIT VALUE IN NR. NET WEIGHT 513.238 KGS
Expand
Product description
ATEM NEBULISER SOLUTION (IPRATROPIUM BROMIDE VIALS) MEDICINE QTY DECLARED IN NR. DUE TO UNIT VALUE IN NR. NET WEIGHT 505.940 KGS
Expand
Product description
ATEM NEBULISER SOLUTION (IPRATROPIUM BROMIDE VIALS) MEDICINE QTY DECLARED IN NR. DUE TO UNIT VALUE IN NR. NET WEIGHT 510.491 KGS
Expand
Product description
(ACTIVE PHARMACEUTICALS INGREDIENTS API FOR THE MANUFACTURING OF BREXIN TABLETS) PIROXICAM BETA-CYCLODEXTRIN CAS NO. 96684-40-1 Note: for CD 5th Schedule Part II of Table-A at Sr. No. 230 for ACD: 1151(I)/2025 Sr. No. 3(iii) Date: 30-06-2025 for RD: 1152/(I)/2025 Sr. No. 2(c) Date: 30-06-2025
Expand
Product description
(ACTIVE PHARMACEUTICALS INGREDIENTS API FOR THE MANUFACTURING OF BREXIN TABLETS) PIROXICAM BETA-CYCLODEXTRIN CAS NO. 96684-40-1 Note: for CD 5th Schedule Part II of Table-A at Sr. No. 230 for ACD: 1151(I)/2025 Sr. No. 3(iii) Date: 30-06-2025 for RD: 1152/(I)/2025 Sr. No. 2(c) Date: 30-06-2025
Expand
Product description
CLENIL AEROSOL NEBULISING SUSPENSION (BECLOMETHASONE MONODOSE VIALS) QTY DECLARED IN NR. DUE TO UNIT VALUE IN NR. NET WEIGHT 1843.20 KGS
Expand
Product description
CUROSURF STERILE SUSPENSION IN VIALS FOR INTRATRACHEAL INSTILLATION GENETIC NAME IS PORACTANT ALFA QTY DECLARED IN NR. DUE TO UNIT VALUE IN NR. NET WEIGHT 30.00 KGS
Expand
chiesi farmaceuticic s.p.a. is italy Buyer&Supplier,
and primarily engages in the import and export business of products such as gh,ty d,unit.
According to the 52wmb.com global trade database, as of 2026-03-31, the company has completed 4225 international trades,
with its main trading regions covering pakistan,colombia,russia etc.
The core products include HS30049099,HS30043900,HS3004902900 etc,
often transported via milano linate,port genoa, port amsterdam etc,
and its main trading partners are chiesi pharamaceuticals pvt ltd.,amarey nova medical s.a.,оао фармстандарт лексредства.
These trade data are sourced from various countries' customs and public channels, and have undergone standardization and structuring processing.
They can reflect the import and export trends and main market layout of the enterprise, and are suitable for market trend analysis, competitor research, port transportation planning, supply chain optimization, and international customer development.
They provide reliable support for cross-border trade decision-making.
The trade data displayed on chiesi farmaceuticic s.p.a. is sourced from the 52wmb.com global trade database. It is based on legal records from customs and related public channels of various countries, and has been formatted and organized for user query and analysis.
We maintain compliance with the source and processing of data to ensure the objectivity of information, but due to the dynamic changes in international trade activities, some data may be delayed or changed.